SARS-CoV-2 spike S2-specific neutralizing antibodies

Since the onset of the coronavirus disease 2019 (COVID-19), numerous neutralizing antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and authorized for emergency use to control the pandemic.Most COVID-19 therapeutic NAbs prevent the S1 subunit Reptile Substrate of the SARS-CoV-2 spike (S) prot

read more